EU Court Rejected Novartis Trademark Challenge
The EU General Court ruled against Swiss firm Novartis in a trademark dispute with competitor Devatis.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should large companies have stronger legal protections against competitors using similar-sounding brand names?
The EU General Court has issued a ruling rejecting a challenge from Novartis regarding the trademark registration of Devatis. Judges determined that the reputation of the Novartis brand was insufficient to block the rival company from registering its name.
Why it matters
This decision clarifies the standards for trademark similarity within the European market. It establishes that established pharmaceutical brands cannot automatically block competitors from registering names that they claim infringe on their reputation.
The ruling involved a single legal trademark registration dispute between Novartis and Devatis. The court decision focused on the strength of brand reputation as a barrier to competitive registration within the European Union.
The players
Novartis
Novartis is a major multinational pharmaceutical corporation headquartered in Switzerland.
Devatis
Devatis is a pharmaceutical company with origins in Turkey that faced the trademark challenge.
EU General Court
The EU General Court is the secondary judicial body of the European Union that handles intellectual property disputes.
The details
The court examined the similarities between the names and determined that the existing footprint of Novartis did not preclude the Turkish company Devatis from its registration. This outcome allows Devatis to proceed with its branding under the current legal framework.
Timeline
September 23, 2026: The EU General Court issued the official ruling.
Market Landscape
This case highlights the ongoing friction between established pharmaceutical giants and emerging market competitors seeking to solidify their brand identities. It reflects the broader industry trend of aggressive intellectual property enforcement as companies fight for market share across international borders.
Average consumers and patients are unlikely to see immediate changes in pricing or product availability resulting from this specific legal decision. The outcome primarily affects how pharmaceutical companies structure their branding and intellectual property strategies in the European market.
The takeaway
Companies must provide substantial evidence beyond brand recognition alone to successfully challenge the trademark registration of a competitor. This ruling emphasizes the high threshold required for global firms to limit the entry of smaller rivals through legal means.
Further reading
For more on industry regulatory developments, visit the Healthcare section.
Source note: This article includes information reported by Mlex.
Live Poll
Should large companies have stronger legal protections against competitors using similar-sounding brand names?
